Surgery Partners Inc.
Find Ratings ReportsSURGERY PARTNERS INC's gross profit margin for the fourth quarter of its fiscal year 2023 is essentially unchanged when compared to the same period a year ago. Sales and net income have grown, and although the growth in revenues has outpaced the average competitor within the subsector, the net income growth has not.
During the same period, stockholders' equity ("net worth") has remained unchanged from the same quarter last year.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
Income Statement | Q4 FY23 | Q4 FY22 |
---|---|---|
Net Sales ($mil) | 735.4 | 707.1 |
EBITDA ($mil) | 172.7 | 155.6 |
EBIT ($mil) | 141.6 | 126.0 |
Net Income ($mil) | -1.0 | -23.4 |
Balance Sheet | Q4 FY23 | Q4 FY22 |
---|---|---|
Cash & Equiv. ($mil) | 195.9 | 282.9 |
Total Assets ($mil) | 6876.7 | 6682.1 |
Total Debt ($mil) | 2775.1 | 2929.7 |
Equity ($mil) | 1987.2 | 1998.2 |
Profitability | Q4 FY23 | Q4 FY22 |
---|---|---|
Gross Profit Margin | 26.33 | 26.06 |
EBITDA Margin | 23.48 | 22.0 |
Operating Margin | 19.25 | 17.82 |
Sales Turnover | 0.4 | 0.38 |
Return on Assets | -0.17 | -0.81 |
Return on Equity | -0.6 | -2.73 |
Debt | Q4 FY23 | Q4 FY22 |
---|---|---|
Current Ratio | 1.71 | 1.87 |
Debt/Capital | 0.58 | 0.59 |
Interest Expense | 0.0 | 52.9 |
Interest Coverage | 0.0 | 2.38 |
Share Data | Q4 FY23 | Q4 FY22 |
---|---|---|
Shares outstanding (mil) | 126.49 | 125.96 |
Div / share | 0.0 | 0.0 |
EPS | -0.01 | -0.23 |
Book value / share | 15.71 | 15.86 |
Institutional Own % | n/a | n/a |
Avg Daily Volume | 987722.0 | 915844.0 |
HOLD. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Conducting a second comparison, its price-to-book ratio of 1.83 indicates a significant discount versus the S&P 500 average of 4.68 and a discount versus the subsector average of 3.19. The current price-to-sales ratio is well below the S&P 500 average, but above the subsector average. The valuation analysis reveals that, SURGERY PARTNERS INC seems to be trading at a premium to investment alternatives.
Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SGRY NM | Peers 21.06 | SGRY 12.38 | Peers 54.00 | |||||||||||||||||||||
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings. SGRY's P/E is negative making this valuation measure meaningless. |
Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. SGRY is trading at a significant discount to its peers. |
|||||||||||||||||||||||
Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
SGRY 22.82 | Peers 15.17 | SGRY NA | Peers 0.67 | |||||||||||||||||||||
Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations. SGRY is trading at a significant premium to its peers. |
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. Ratio not available. |
|||||||||||||||||||||||
Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
SGRY 1.83 | Peers 3.19 | SGRY 82.76 | Peers 33.66 | |||||||||||||||||||||
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. SGRY is trading at a significant discount to its peers. |
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. SGRY is expected to have an earnings growth rate that significantly exceeds its peers. |
|||||||||||||||||||||||
Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
SGRY 1.33 | Peers 1.25 | SGRY 8.03 | Peers 10.95 | |||||||||||||||||||||
Average. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. SGRY is trading at a valuation on par with its subsector on this measurement. |
Lower. A sales growth rate that trails the subsector implies that a company is losing market share. SGRY significantly trails its peers on the basis of sales growth. |
|||||||||||||||||||||||